Amgen, Inc.  

(Public, NASDAQ:AMGN)   Watch this stock  
Find more results for AMGN
161.58
+2.70 (1.70%)
Pre-market: 163.48 +1.90 (1.18%)
Oct 31, 7:21AM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 158.16 - 161.58
52 week 108.20 - 161.58
Open 158.64
Vol / Avg. 4,131.00/4.66M
Mkt cap 120.69B
P/E 25.43
Div/yield 0.61/1.51
EPS 6.35
Shares 761.00M
Beta 0.54
Inst. own 81%
Jan 26, 2015
Q4 2014 Amgen Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 11, 2014
Amgen Inc at Credit Suisse Healthcare Conference - 10:30AM EST - Add to calendar
Oct 28, 2014
Amgen Inc 2014 Business Review Meeting - Webcast
Oct 27, 2014
Q3 2014 Amgen Inc Earnings Call - Webcast
Oct 27, 2014
Q3 2014 Amgen Inc Earnings Release
Sep 29, 2014
Amgen Inc Conference Call on Kyprolis at ESMO - Webcast
Sep 10, 2014
Amgen at Morgan Stanley Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 24.73% 27.21%
Operating margin 29.14% 31.41%
EBITD margin - 39.90%
Return on average assets 7.11% 8.44%
Return on average equity 20.08% 24.69%
Employees 20,000 -
CDP Score - 76 B

Address

One Amgen Center Drive
THOUSAND OAKS, CA 91320-1799
United States - Map
+1-805-4471000 (Phone)
+1-805-4471010 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha
About Company - Wikipedia

Description

Amgen Inc. is a global biotechnology pioneer that discovers, develops, manufactures and delivers human therapeutics. Its medicines help millions of patients in the fight against cancer, kidney disease, rheumatoid arthritis (RA), bone disease, and other serious illnesses. On December 10, 2012, the Company acquired all of the outstanding stock of deCODE Genetics (deCODE). In July 5, 2012, the Company acquired KAI Pharmaceuticals, a privately held company based in South San Francisco. In September 2013, Swedish Orphan Biovitrum AB (publ) (Sobi) announced that they have acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen Inc for all therapeutic indications.

Officers and directors

Robert A. Bradway Chairman of the Board, President, Chief Executive Officer
Age: 51
Bio & Compensation  - Reuters
David W. Meline Chief Financial Officer, Executive Vice President
Age: 56
Bio & Compensation  - Reuters
Madhavan Balachandran Executive Vice President - Operations
Age: 63
Bio & Compensation  - Reuters
Sean E. Harper Executive Vice President - Research and Development
Age: 51
Bio & Compensation  - Reuters
Anthony C. Hooper Executive Vice President - Global Commercial Operations
Age: 59
Bio & Compensation  - Reuters
Brian M. McNamee Executive Vice President - Full Potential Initiatives
Age: 57
Bio & Compensation  - Reuters
Cynthia M. Patton Senior Vice President, Chief Compliance Officer
Age: 52
Bio & Compensation  - Reuters
David J. Scott Senior Vice President, General Counsel, Secretary
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Stuart A. Tross Senior Vice President - Human Resources
Age: 47
Bio & Compensation  - Reuters
Steven K. Galson M.D. Senior Vice President - Global Regulatory Affairs And Safety
Age: 57
Bio & Compensation  - Reuters